Finding gives boost to fighting cancer through cell metabolism

A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.

Charles Caskey, Ph.D., has received a cancer research grant from The Mary Kay Foundation to study how focused ultrasound therapy could be an ideal helper for immunotherapy.

Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program, has been named a Komen Scholar for her leadership in breast cancer research. She is joined by Wayne Dornan, PhD, a patient research advocate at VICC, who will serve on the Advocates in Science Steering Committee for Susan G. Komen.

Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Many women who receive chemotherapy for breast cancer report problems with their thinking, memory and attention after treatment. And as the survival rates for breast cancer increase, so do these issues associated with chemotherapy. Paul Newhouse, M.

Justin Balko, Pharm.D., Ph.

Leading cancer investigators from Vanderbilt-Ingram Cancer Center will unveil the latest in cancer research during an upcoming community event. “Precision Medicine in Cancer: At the Crossroads of Research and Treatment for Patients” will be held Tuesday, May 10, from 5:

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […]